BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today an…
Category: Business
$4.8 Billion Worldwide Ocular Implants Industry to 2027 – Impact of COVID-19 on the Market – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ocular Implants – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. Amid the COVID-19 crisis and the looming economic recession, the Ocular Implants market worldwide will…
Insights on the Soft Contact Lens Global Market to 2027 – Players Include Menicon, Novartis & Sensimed Among Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Soft Contact Lens – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. Amid the COVID-19 crisis and the looming economic recession, the Soft Contact Lens market worldwide …
Glaukos Announces Presentation Cancellation at the William Blair 40th Annual Growth Stock Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that …
Lineage Cell Therapeutics to Host Therapeutic Expert Call Today to Discuss the First Known Reported Finding of Retinal Tissue Regeneration with OpRegen® in Dry AMD with Geographic Atrophy
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage cell therapy company which manufactures and transplants specific cell types to treat diseases and serious medical conditi…
Global Ambulatory Healthcare Services Market (2019 to 2027) – Impact of COVID-19 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ambulatory Healthcare Services – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. Amid the COVID-19 crisis and the looming economic recession, the Ambulatory Healthcare …
Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseas…
Samenvatting: Re-Vana Therapeutics haalt $3,25 miljoen op in Pre-Series A-financing
BELFAST, Noord-Ierland–(BUSINESS WIRE)–Re-Vana Therapeutics Ltd, een particulier gespecialiseerd bedrijf voor therapeutische en medicijnafgifte dat geneesmiddelen met aanhoudende afgifte voor belangrijke gezichtsbedreigende oogziekten, heeft vandaag …
Re-Vana Therapeutics lève 3,25 millions de dollars dans un financement de pré-série A
BELFAST, Irlande du Nord–(BUSINESS WIRE)–Re-Vana Therapeutics Ltd, une société privée de thérapies spécialisées et d’administration médicamenteuse développant des agents thérapeutiques à libération prolongée pour lutter contre des pathologies oculair…
Re-Vana Therapeutics wirbt 3,25 Millionen USD in einer Serie A Vorfinanzierungsrunde ein
BELFAST, Nordirland–(BUSINESS WIRE)–Re-Vana Therapeutics Ltd ist ein in Privatbesitz befindliches Unternehmen für Spezialtherapeutika und Medikamentenverabreichung, das Therapeutika mit verzögerter Wirkstofffreisetzung für schwere, sehkraftbedrohende…
Harbour BioMed Receives Chinese Regulatory Approval of IND Application to Begin Seamless Phase 2/3 Clinical Trial of HBM9161 in Graves’ Ophthalmopathy
CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands & SUZHOU, China–(BUSINESS WIRE)–Harbour BioMed receives IND approval in China to begin seamless Phase 2/3 clinical trial of HBM9161 in Graves’ ophthalmopathy.
VisionQuest Biomedical Inc. and The University of New Mexico Combine Artificial Intelligence and Infrared Imaging to Diagnose Early Signs of Diabetic Foot
ALBUQUERQUE, N.M.–(BUSINESS WIRE)– #ai–VisionQuest Biomedical Inc. and the University of New Mexico School of Medicine have been awarded a three-year $3 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),…
Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With Geographic Atrophy
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage cell therapy company which manufactures and transplants specific cell types to treat diseases and serious medical conditi…
EyeSouth Partners Enters Sixth State With Coastal Eye Associates of Texas Affiliation
ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is pleased to announce that it has completed an affiliation with Coastal Eye Associates (“CEA”). The affiliation represents EyeSouth’s first in the state of Texas and sixteenth a…
Plano Sunglasses Market 2020-2024 | Product Innovation to Boost Growth | Technavio
LONDON–(BUSINESS WIRE)– #GlobalPlanoSunglassesMarket–The Global Plano Sunglasses Market will grow by USD 4.52 bn during 2020-2024
Ocular Therapeutix™ to Present at the Jefferies Virtual Healthcare Conference
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today an…
Impact of the Coronavirus on the Worldwide Ophthalmology Drugs Industry to 2030 – Identify Growth Segments for Investment – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Drugs Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery” report has been added to ResearchAndMarkets.com’s offering. This report provides the strategists, marketers and senior m…
Simulations Plus Receives New Grant Award from the FDA
LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus today announced that it has received a new Grant Award from the FDA to enhance the ocular (OCAT) model in its GastroPlus software.
Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients
Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in peopl…